Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 5,438 shares at $125.69 ($684K) on 2017-02-06, disclosed to the SEC on 2017-02-08.
Open-market sale of $684k ALXN by EVP & Global Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $125.69 | 2,710 | $341K | 49.8% |
| 2 | $125.69 | 2,710 | $341K | 49.8% |
| 3 | $126.88 | 18 | $2K | 0.3% |
| Total | $125.69 avg | 5,438 | $684K | 100% |
| Filing → |
| ALXN | SELL | 2017-02-10 | $28K | — | Filing → |
| ALXN | SELL | 2016-05-18 | $1.1M | — | Filing → |
| ALXN | SELL | 2016-03-01 | $139K | — | Filing → |